background
new
approach
urgent
need
fight
influenza
viral
infect
previou
research
shown
zirconia
nanoparticl
use
anticanc
materi
antivir
activ
report
investig
antivir
effect
zirconia
zro
nanoparticl
np
highli
pathogen
avian
influenza
viru
materi
method
studi
antivir
effect
zro
viru
assess
vivo
molecular
mechan
respons
protect
investig
result
mice
treat
nm
positivelycharg
np
dose
mgkg
show
higher
surviv
rate
smaller
reduct
weight
nm
zro
activ
matur
dendrit
cell
initi
promot
express
cytokin
associ
antivir
respons
innat
immun
lung
mice
zro
treatment
led
less
patholog
lung
injuri
signific
reduct
influenza
viru
replic
overexpress
proinflammatori
cytokin
conclus
antivir
studi
use
zirconia
np
show
protect
mice
highli
pathogen
avian
influenza
viru
suggest
strong
applic
potenti
method
introduc
new
tool
wide
rang
microbi
infect
recent
year
larg
number
rapidlyspread
viral
outbreak
place
consider
demand
healthcar
infrastructur
spark
global
concern
emerg
sever
acut
respiratori
syndrom
coronaviru
sarscov
influenza
pandem
pandem
strain
influenza
viru
iav
devast
ebola
zika
viru
epidem
illustr
sever
outbreak
among
virus
avian
influenza
viru
attract
great
deal
attent
due
rapid
spread
high
pathogen
worldwid
lead
caus
death
infect
patient
diffus
alveolar
damag
hemorrhag
lung
caus
overact
inflammatori
respons
overproduct
inflammatori
cytokin
mice
human
refer
cytokin
storm
identifi
main
caus
death
associ
viru
vaccin
remain
effect
prevent
measur
influenza
virus
nevertheless
vaccin
effect
decreas
new
variant
aris
antigen
drift
shift
although
antivir
drug
zanamivir
relenza
oseltamivir
tamiflu
current
use
increas
emerg
drugresist
strain
affect
clinic
applic
therefor
develop
novel
broadspectrum
prophylact
therapeut
agent
iav
urgent
need
recent
decad
nanoparticl
np
increasingli
appli
inexpens
easytous
detect
method
well
promis
adjuv
viral
infect
due
uniqu
physic
chemic
characterist
strong
activ
immun
system
due
structur
chemic
properti
nanomateri
sever
advantag
bulk
materi
composit
includ
small
size
high
surfac
areatovolum
ratio
eas
prepar
modif
np
affect
immun
respons
bind
serum
protein
previou
studi
np
shown
specif
immunomodulatori
effect
immun
cell
well
antivir
antioxid
anticanc
capabl
particular
viruslik
particl
alundum
mesopor
silica
receiv
great
attent
potenti
applic
adjuv
howev
protein
dna
vaccin
exhibit
poor
stabil
vivo
report
np
use
effici
antigen
deliveri
system
although
np
enhanc
immun
studi
date
focus
antivir
function
np
rather
use
protein
dna
carrier
nanomaterialactiv
immun
respons
must
overcom
np
use
carrier
date
littl
attent
paid
antivir
effect
np
without
virusbas
antigen
nanoparticl
zro
nanos
hollow
colloid
metal
oxid
control
thick
synthes
use
robust
solgel
process
show
superior
catalyt
activ
mani
reaction
due
uniqu
physicochem
characterist
surfac
zro
zro
wide
use
catalyst
mani
engin
applic
offer
environmentallyfriendli
option
chemic
pharmaceut
industri
also
use
anticanc
agent
treatment
colon
cancer
despit
potenti
biomed
applic
studi
report
use
zro
antivir
materi
present
studi
seri
np
investig
regard
particl
size
surfac
charg
composit
npmediat
protect
anim
highli
pathogen
avian
influenza
viru
infect
result
show
zro
optim
physic
chemic
characterist
could
reduc
mous
mortal
allevi
respiratori
patholog
chang
inhibit
viral
replic
lung
mice
treatment
zro
prior
influenza
infect
caus
prompt
initi
host
antivir
respons
allevi
damag
induc
cytokin
storm
infect
first
report
vivo
antivir
effect
zro
infect
provid
comprehens
lowcost
method
protect
human
anim
variou
viral
infect
sixsevenweeksold
femal
balbc
mice
purchas
vital
river
laboratori
beij
china
sn
prepar
previous
describ
briefli
sn
synthes
twostep
selectiveetch
method
first
step
organicinorgan
hybrid
solid
silica
sphere
hssss
elabor
design
threelay
sandwich
structur
core
outer
layer
shell
made
pure
silica
framework
hydrolyz
tetraethylorthosilan
teo
middl
layer
compris
organ
silica
cocondens
teo
n
trimethoxysilyl
propyl
ethylenediamin
tsd
second
step
hssss
convert
sn
appropri
amount
aqueou
hydrofluor
acid
zro
prepar
previous
describ
briefli
sn
employ
templat
sn
underw
dewat
process
prior
dispers
mixtur
alcohol
acetonitril
ammonia
ad
adjust
ph
weakli
alkalin
valu
zirconium
precursor
slowli
inject
mixtur
magnet
stir
hydrolysi
zirconium
trigger
weakli
alkalin
environ
induc
growth
small
zro
use
sn
seed
h
reaction
zro
shell
gradual
form
surfac
sn
seed
thick
shell
control
adjust
reaction
time
zr
sn
ratio
remov
sn
seed
core
naoh
solut
ml
ad
follow
reaction
approxim
h
zro
np
thu
obtain
collect
centrifug
wash
three
time
deioniz
water
prepar
polystyren
ps
prepar
previous
describ
briefli
g
freshli
distil
styren
merck
mg
hexadecan
mg
fluoresc
dye
n
mg
hydrophob
initi
ad
g
water
contain
mg
surfact
cetyltrimethylammonium
chlorid
stir
h
preemulsif
miniemuls
prepar
sonif
amplitud
prevent
polymer
polymer
carri
overnight
synthesi
surfact
remov
amicon
ultrafiltr
kda
extens
dialysi
wash
use
particl
suspens
dispers
sonif
morpholog
structur
np
observ
transmiss
electron
microscop
averag
size
surfac
charg
zro
np
glucos
measur
zetas
particl
analyz
malvern
compani
uk
nanomateri
glucos
administ
intraperiton
mice
twice
one
day
apart
second
day
administr
viral
challeng
given
influenza
viru
use
studi
isol
infect
chicken
flock
lethal
dose
determin
mice
follow
serial
dilut
stock
phosphatebuff
salin
pb
mice
anesthet
zoletil
virbac
carro
franc
infect
dose
tripl
intranas
rout
accord
previous
publish
method
seven
mice
per
group
use
experi
period
day
bodi
weight
determin
everi
day
lung
tissu
sampl
collect
day
postinfect
experi
viru
conduct
biosafeti
level
contain
laboratori
anim
experi
approv
anim
ethic
committe
china
agricultur
univers
approv
number
accord
regul
experiment
anim
beij
author
furthermor
experiment
protocol
conform
guidelin
beij
laboratori
anim
welfar
ethic
committe
approv
beij
associ
scienc
technolog
approv
number
day
postinfect
lung
tissu
sampl
three
mice
per
group
collect
fix
neutral
formalin
room
temperatur
h
histopatholog
viral
antigen
analys
lung
tissu
day
postinfect
perform
use
hematoxylin
eosin
h
e
stain
ihc
stain
previous
describ
briefli
serial
tissu
section
cut
thick
embed
paraffin
slide
stain
h
e
examin
use
light
microscopi
olympu
ihc
stain
section
incub
normal
goat
serum
pb
min
block
nonspecif
bind
site
prior
reaction
antiinfluenza
nucleoprotein
mab
abcam
dilut
pb
h
slide
incub
goat
antimous
igg
conjug
avidin
chemicon
usa
h
follow
incub
biotinyl
peroxidas
victoria
bc
canada
addit
h
stain
visual
addit
sigmaaldrich
st
loui
mo
usa
min
counterstain
hematoxylin
slide
mount
neutral
balsam
patholog
chang
evalu
veterinari
pathologist
score
blind
studi
descript
lung
score
follow
microscop
lesion
extrem
mild
character
mild
interstiti
edema
desquam
rare
epitheli
cell
mild
character
interstiti
edema
thicken
alveolar
wall
occasion
bronchial
structur
damag
moder
character
hyperemia
hemorrhag
interstiti
edema
thicken
alveolar
wall
bronchial
structur
damag
slight
infiltr
inflammatori
cell
sever
character
hyperemia
hemorrhag
interstiti
edema
thicken
alveolar
wall
seriou
bronchial
structur
damag
greater
infiltr
quantit
pcr
qpcr
enzymelink
immunosorb
assay
elisa
qpcr
elisa
analys
conduct
previous
describ
briefli
total
rna
extract
approxim
mg
lung
spleen
tissu
homogen
trizol
reagent
invitrogen
carlsbad
ca
usa
cdna
revers
transcrib
use
easyscript
firststrand
cdna
synthesi
super
mix
transgen
biotech
beij
china
accord
manufactur
instruct
realtim
pcr
perform
triplic
use
power
sybr
green
pcr
master
mix
kit
appli
biosystem
warrington
uk
appli
biosystem
system
express
hemagglutinin
ha
gene
measur
use
absolut
quantif
method
amplif
perform
follow
min
follow
cycl
copi
number
calcul
use
hacontain
plasmid
known
concentr
standard
express
level
interferon
ifn
monocyt
chemoattract
protein
mcp
interleukin
il
interferoninduc
protein
ip
tumor
necrosi
factor
tnf
measur
use
rel
quantif
method
normal
result
control
glucos
group
use
method
forward
primer
acc
ttc
aac
acc
ccg
revers
primer
tca
cgc
acg
att
tcc
intern
standard
amplif
perform
follow
min
follow
cycl
cytokin
primer
list
tabl
addit
detect
protein
express
cytokin
perform
use
elisa
kit
accord
manufactur
instruct
madindarbi
canin
kidney
mdck
cell
cultur
dulbecco
modifi
eagl
medium
dmem
hyclon
laboratori
logan
ut
usa
contain
fetal
bovin
serum
hyclon
laboratori
uml
penicillin
streptomycin
right
lung
homogen
individu
mice
prepar
dilut
dmem
ad
monolay
mdck
cell
semisolid
agar
contain
trypsintolylsulfonyl
phenylalanyl
chloromethyl
keton
tpck
sigma
beij
china
cultur
incub
co
h
fix
stain
crystal
violet
plaqueform
unit
pfu
count
fluoresc
conjug
rat
antimous
monoclon
antibodi
includ
antimhciip
purchas
ebiosci
san
diego
ca
usa
three
noninfect
mice
group
sacrif
day
anoth
three
day
follow
intraperiton
administr
singlecel
suspens
isol
spleen
stimul
cell
fix
paraformaldehyd
permeabil
saponin
sigmaaldrich
complet
intracellular
stain
cell
doublestain
antibodi
min
fluoresc
intens
measur
facsvers
system
analyz
flowjo
softwar
bd
bioscienc
san
jose
ca
usa
statist
analysi
perform
use
twoway
analysi
varianc
graphpad
prism
version
graphpad
softwar
san
diego
ca
usa
softwar
packag
pvalu
consid
repres
statist
signific
differ
studi
protect
effect
np
iav
infect
vivo
three
kind
np
name
zro
sn
ps
administr
twice
intraperiton
mice
mgkg
one
day
apart
np
prepar
accord
previou
studi
three
size
nm
zro
show
good
monodispers
glucos
solut
figur
particl
approxim
nm
diamet
observ
use
transmiss
electron
microscopi
tabl
show
hydrodynam
diamet
particl
character
use
zetas
np
modifi
polyethylen
glycol
carboxyl
amidogen
obtain
particl
similar
posit
neutral
surfac
charg
np
administ
mice
intraperiton
two
dose
one
day
apart
day
second
np
administr
viral
challeng
given
tripl
seven
mice
per
group
use
experi
period
day
shown
figur
figur
zro
sn
ps
differ
diamet
nm
administ
four
mice
die
glucos
group
one
anim
die
nm
sn
zro
treatment
group
death
observ
nm
ps
treatment
group
accord
size
effect
surviv
rate
mice
nm
zro
group
significantli
higher
glucos
group
nm
zro
group
nm
zro
group
moreov
averag
bodi
weight
mice
treat
np
nm
higher
group
throughout
experiment
period
result
thu
indic
np
provid
protect
particlesizedepend
best
protect
offer
nm
particl
size
effect
surfac
charg
np
antivir
efficaci
studi
use
nm
np
posit
neg
charg
zro
sn
ps
np
charg
administ
mice
mgkg
shown
figur
figur
compar
glucos
group
mice
die
one
mous
die
group
treat
posit
np
surviv
rate
mice
glucos
group
pzro
nzro
group
surviv
rate
respect
signific
differ
found
glucos
negativelycharg
np
term
death
rate
result
show
positivelycharg
np
confer
higher
surviv
rate
constant
bodi
weight
therebi
provid
enhanc
protect
numer
studi
discuss
relationship
np
physicochem
properti
biolog
effect
report
shown
particl
size
play
import
role
biolog
effect
np
includ
cellular
uptak
toxic
size
play
key
role
physiolog
respons
biodistribut
elimin
variou
materi
furthermor
surfac
modif
np
critic
may
lead
alter
cellular
uptak
endosom
escap
np
lin
et
al
report
particl
uptak
cell
increas
follow
trend
surfac
charg
result
present
studi
suggest
positivelycharg
np
appropri
size
stronger
antivir
effect
compar
negativelycharg
np
explor
whether
effect
np
infect
dosedepend
experi
perform
use
zro
sn
ps
differ
dosag
found
np
could
dramat
increas
surviv
rate
reduc
averag
bodi
weight
mice
within
narrow
rang
compar
glucos
group
surviv
rate
mice
mgkg
zro
mgkg
zro
mgkg
zro
group
significantli
higher
glucos
group
although
surviv
rate
show
modest
differ
among
dosag
np
rang
weight
loss
reduc
increas
dosag
figur
figur
togeth
result
suggest
nm
positivelycharg
zro
dosag
mgkg
could
improv
surviv
mice
investig
whether
zro
could
affect
viru
infect
balbc
mice
receiv
dose
tripl
second
day
np
administr
via
intraperiton
inject
day
postinfect
lung
tissu
sampl
three
mice
per
group
collect
histopatholog
analysi
realtim
pcr
shown
figur
examin
histopatholog
chang
lung
mice
day
lung
lesion
glucos
group
includ
inflammatori
cellular
infiltr
necrosi
mucou
epithelium
bronchiol
interstiti
edema
thicken
alveolar
wall
alveolar
lumen
fill
edema
fluid
mix
exfoli
alveolar
epitheli
cell
erythrocyt
inflammatori
cell
also
observ
control
group
howev
symptom
appear
mitig
zro
group
similar
symptom
observ
glucos
group
seen
mgkg
zro
group
lesion
sever
lower
mgkg
zro
mgkg
zro
group
show
interstiti
edema
surround
lung
tissu
inflammatori
cell
infiltr
observ
small
blood
vessel
bronchi
lung
tissu
mice
mgkg
zro
group
show
markedli
milder
symptom
group
control
group
show
histopatholog
chang
score
patholog
chang
lung
mice
determin
result
suggest
np
could
allevi
lung
lesion
mice
glucos
group
iav
antigen
observ
mucos
epithelium
cell
decidu
alveolar
cell
lamina
propria
bronchiol
lung
mice
ihc
analysi
presenc
antigen
zro
group
sporad
figur
mgkg
zro
mgkg
zro
group
low
level
posit
signal
observ
alveolar
cell
lamina
propria
bronchiol
furthermor
posit
signal
distribut
lamina
propria
bronchiol
detect
mgkg
zro
group
posit
cell
observ
control
group
score
iav
antigen
lung
mice
determin
investig
influenc
zro
replic
iav
vivo
viral
load
lung
tissu
virusinfect
mice
examin
shown
figur
ha
copi
number
pfu
valu
zro
group
day
postinfect
lower
glucosetr
mice
mgkg
zro
group
show
signific
differ
p
day
postinfect
pulmonari
viral
titer
zro
group
significantli
lower
glucosetr
mice
extrem
signific
differ
found
mgkg
zro
mgkg
zro
group
p
viral
titer
result
accord
result
ihc
stain
taken
togeth
zro
reduc
lung
injuri
viral
replic
mice
activ
matur
dc
critic
innat
adapt
immun
initi
immun
respons
express
costimulatori
marker
dc
surfac
relat
abil
induc
suppress
immun
respons
mhcii
express
thu
proport
mhcii
cell
among
mous
cell
day
intraperiton
zro
administr
determin
use
fluorescenceactiv
cell
sort
fac
figur
mhcii
express
level
zro
group
higher
control
group
signific
differ
mgkg
zro
glucos
group
p
notabl
found
higher
dosag
zro
result
lower
express
due
toxic
zro
normal
mice
data
suggest
nm
zro
promot
mhcii
express
cell
mice
favor
affect
matur
dc
crucial
innat
immun
antivir
respons
examin
effect
zro
cytokin
express
mice
mrna
level
spleen
mice
day
intraperiton
administr
examin
mrna
level
zro
group
upregul
compar
glucos
group
mgkg
zro
treatment
express
level
cytokin
increas
significantli
mrna
level
mgkg
zro
group
lowest
among
three
zro
group
due
toxic
zro
mice
figur
furthermor
mrna
express
profil
cytokin
zro
group
day
intraperiton
administr
higher
day
data
suggest
zro
promot
express
cytokin
associ
antivir
respons
innat
immun
consist
fac
result
found
zro
effect
enhanc
innat
immun
mice
mechanist
analysi
evalu
express
level
cytokin
lung
infect
mice
administ
np
use
qpcr
figur
compar
glucos
group
mrna
level
mice
zro
group
reduc
mgkg
zro
group
show
significantli
lower
express
level
p
combin
histopatholog
analys
detect
ha
copi
number
result
confirm
np
allevi
patholog
injuri
reduc
viral
level
lung
degrad
cytokin
storm
cytokin
storm
occur
excess
level
proinflammatori
cytokin
induc
acut
mononuclear
neutrophil
inflammatori
respons
elisa
result
also
show
significantli
lower
protein
express
level
cytokin
mgkg
zro
group
compar
group
day
postinfect
consist
result
qpcr
figur
present
studi
found
positivelycharg
zro
nm
reduc
product
cytokin
involv
cytokin
storm
consequ
protect
anim
viral
infect
influenza
viru
one
common
respiratori
pathogen
worldwid
first
major
epidem
highli
pathogen
avian
influenza
viru
occur
hong
kong
sinc
becom
well
known
potenti
caus
global
pandem
human
mammal
age
consider
risk
morbid
high
fatal
rate
consid
grow
threat
public
health
around
world
date
classifi
list
diseas
world
organis
anim
health
oie
categori
anim
diseas
china
varieti
antivir
drug
vaccin
adopt
prevent
control
influenzainduc
ill
howev
remain
difficult
limit
spread
virus
due
highli
contagi
natur
frequent
mutat
viral
gene
emerg
resist
influenza
strain
due
widespread
abus
antivir
drug
therefor
new
approach
fight
influenza
viru
infect
urgent
need
due
uniqu
structur
chemic
characterist
includ
larg
surfac
area
strong
target
perform
good
biocompat
high
adsorpt
capac
np
mani
benefit
convent
materi
therefor
np
wide
appli
clinic
trial
carrier
antitumor
drug
np
significantli
improv
cur
effect
tumor
therapi
reduc
toxic
drug
side
effect
make
attract
candid
cancer
therapi
antivir
therapi
np
use
adjuv
carrier
enhanc
immun
respons
howev
np
commonli
use
effici
antigen
deliveri
system
antivir
effect
recent
report
herein
demonstr
np
alon
effect
inhibit
viral
replic
mous
model
protect
mice
infect
data
confirm
feasibl
use
np
alon
therapeut
agent
control
influenza
infect
influenza
viru
caus
sever
respiratori
diseas
human
mammal
clinic
symptom
includ
fever
muscl
ach
cough
headach
diarrhea
viral
pneumonia
enceph
acut
respiratori
distress
syndrom
ard
mous
model
caus
hair
thicken
bow
limb
blind
trembl
signific
weight
loss
sever
patholog
tissu
chang
even
death
previou
studi
shown
virusinduc
acut
lung
injuri
ard
trigger
cytokin
storm
seriou
consequ
inflamm
result
releas
proinflammatori
cytokin
recruit
immun
cell
infect
area
excess
inflamm
caus
system
inflammatori
respons
syndrom
bodi
enter
state
high
metabol
activ
energi
usag
high
level
proinflammatori
cytokin
includ
detect
human
mice
infect
highli
pathogen
influenza
viru
present
studi
investig
antivir
effect
positivelycharg
zro
iav
figur
overview
find
positivelycharg
zro
nm
size
mgkg
dose
confer
protect
infect
mice
mechan
relat
zro
mediat
enhanc
innat
immun
earli
stage
infect
appropri
nanoparticl
treatment
could
reduc
viral
load
suppress
inflammatori
cytokin
storm
lung
mice
thu
prevent
lung
injuri
improv
surviv
rate
infect
mice
mous
model
mechan
action
np
sever
studi
shown
posit
charg
facilit
retent
np
cell
rel
long
time
like
relat
intracellular
agglomer
nativ
surfac
chemistri
np
also
play
crucial
role
exocytosi
pattern
cell
provid
first
data
positivelycharg
zro
np
downregul
level
proinflammatori
cytokin
therebi
allevi
inflammatori
respons
make
effect
antiinflammatori
agent
highli
pathogen
influenza
viru
present
studi
seem
paradox
mgkg
zro
np
less
effect
activ
dc
appear
effect
protect
compar
lower
dose
previou
research
team
research
system
toxic
zro
np
demonstr
dosag
zro
rang
mgkg
safe
effect
clinic
use
howev
found
mgkg
zro
np
seem
mild
advers
reaction
mice
show
slightli
low
spirit
day
intraperiton
administr
thu
consid
clinic
phenomenon
may
lead
lower
express
immun
indic
spleen
mgkg
zro
group
compar
mgkg
zro
np
mgkg
zro
np
mgkg
zro
np
group
show
dramat
increas
time
increas
indic
grow
power
immun
respons
suppos
mgkg
zro
np
group
show
better
immun
respons
day
day
intraperiton
administr
investig
futur
studi
due
np
could
carri
lung
circul
specul
mgkg
zro
np
carri
lung
effect
viral
infect
compar
mgkg
np
mgkg
zro
np
mgkg
zro
np
activ
antivir
respons
lung
eventu
provid
best
protect
mice
fight
viru
demonstr
positivelycharg
zro
nm
size
mgkg
dose
confer
protect
infect
mice
figur
mechan
protect
relat
zro
mediat
enhanc
innat
immun
earli
stage
infect
appropri
np
treatment
could
reduc
viral
load
suppress
inflammatori
cytokin
storm
lung
mice
thu
allevi
lung
injuri
improv
surviv
rate
infect
mice
antivir
studi
use
zirconia
np
suggest
strong
potenti
applic
novel
treatment
wide
rang
microbi
infect
zro
np
effect
protect
mice
highli
pathogen
infect
zro
np
enhanc
innat
immun
promot
cytokin
releas
mice
zro
np
improv
surviv
rate
mice
allevi
lung
injuri
zro
np
reduc
viral
load
suppress
inflammatori
storm
mice
data
gener
analyz
studi
includ
publish
articl
